HUE059506T2 - Az 1-((2R,4R)-2-(1H-benzo[d]imidazol-2-il)-1-metilpiperidin-4-il)-3-(4--cianofenil)karbamid-maleát kristályos formájának elõállítási eljárása és az 1-((2R,4R)-2-(1H-benzo[d]imidazol-2-il)-1-metilpiperidin-4-il)-3-(4--cianofenil)karbamid-imidazol komplex (1:1) kristályos formája - Google Patents

Az 1-((2R,4R)-2-(1H-benzo[d]imidazol-2-il)-1-metilpiperidin-4-il)-3-(4--cianofenil)karbamid-maleát kristályos formájának elõállítási eljárása és az 1-((2R,4R)-2-(1H-benzo[d]imidazol-2-il)-1-metilpiperidin-4-il)-3-(4--cianofenil)karbamid-imidazol komplex (1:1) kristályos formája

Info

Publication number
HUE059506T2
HUE059506T2 HUE20151107A HUE20151107A HUE059506T2 HU E059506 T2 HUE059506 T2 HU E059506T2 HU E20151107 A HUE20151107 A HU E20151107A HU E20151107 A HUE20151107 A HU E20151107A HU E059506 T2 HUE059506 T2 HU E059506T2
Authority
HU
Hungary
Prior art keywords
methylpiperidin
cyanophenyl
imidazol
benzo
crystalline form
Prior art date
Application number
HUE20151107A
Other languages
English (en)
Hungarian (hu)
Inventor
Eric Christian Hansen
Christopher Scott Seadeek
Anil Mahadeo Rane
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55806563&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HUE059506(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer filed Critical Pfizer
Publication of HUE059506T2 publication Critical patent/HUE059506T2/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
HUE20151107A 2015-04-24 2016-04-13 Az 1-((2R,4R)-2-(1H-benzo[d]imidazol-2-il)-1-metilpiperidin-4-il)-3-(4--cianofenil)karbamid-maleát kristályos formájának elõállítási eljárása és az 1-((2R,4R)-2-(1H-benzo[d]imidazol-2-il)-1-metilpiperidin-4-il)-3-(4--cianofenil)karbamid-imidazol komplex (1:1) kristályos formája HUE059506T2 (hu)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562152108P 2015-04-24 2015-04-24

Publications (1)

Publication Number Publication Date
HUE059506T2 true HUE059506T2 (hu) 2022-11-28

Family

ID=55806563

Family Applications (2)

Application Number Title Priority Date Filing Date
HUE20151107A HUE059506T2 (hu) 2015-04-24 2016-04-13 Az 1-((2R,4R)-2-(1H-benzo[d]imidazol-2-il)-1-metilpiperidin-4-il)-3-(4--cianofenil)karbamid-maleát kristályos formájának elõállítási eljárása és az 1-((2R,4R)-2-(1H-benzo[d]imidazol-2-il)-1-metilpiperidin-4-il)-3-(4--cianofenil)karbamid-imidazol komplex (1:1) kristályos formája
HUE16718016A HUE048664T2 (hu) 2015-04-24 2016-04-13 1-((2R,4R)-2-(1H-benzo[D]imidazol-2-il)-l-metilpiperidin-4-il)-3-(4-cianofenil)-karbamid-maleát kristályformái

Family Applications After (1)

Application Number Title Priority Date Filing Date
HUE16718016A HUE048664T2 (hu) 2015-04-24 2016-04-13 1-((2R,4R)-2-(1H-benzo[D]imidazol-2-il)-l-metilpiperidin-4-il)-3-(4-cianofenil)-karbamid-maleát kristályformái

Country Status (24)

Country Link
US (4) US10414748B2 (enExample)
EP (2) EP3666768B1 (enExample)
JP (1) JP6345728B2 (enExample)
KR (2) KR102078444B1 (enExample)
CN (1) CN107531667A (enExample)
AR (1) AR104391A1 (enExample)
AU (1) AU2016251940C1 (enExample)
BR (1) BR112017021075B1 (enExample)
CA (2) CA2983387C (enExample)
CY (2) CY1124056T1 (enExample)
DK (2) DK3286176T3 (enExample)
ES (2) ES2923593T3 (enExample)
HK (1) HK1243416A1 (enExample)
HU (2) HUE059506T2 (enExample)
IL (1) IL255224B (enExample)
MX (1) MX375384B (enExample)
PL (2) PL3666768T3 (enExample)
PT (2) PT3666768T (enExample)
RU (1) RU2717564C2 (enExample)
SG (1) SG11201707863QA (enExample)
SI (2) SI3666768T1 (enExample)
TW (1) TWI646093B (enExample)
WO (1) WO2016170451A1 (enExample)
ZA (1) ZA201706391B (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112017021075B1 (pt) 2015-04-24 2021-08-03 Pfizer Inc. Forma cristalina de maleato de 1-((2r,4r)-2-(1h- benzo[d]imidazol-2-il)-1-metilpiperidin-4-il)-3-(4- cianofenil)ureia e composição farmacêutica
US20230107634A1 (en) * 2020-01-28 2023-04-06 Teva Pharmaceuticals International Gmbh Processes for the preparation of glasdegib and salt thereof and solid state forms of glasdegib maleate and process for preparation thereof
EP4126237B1 (en) 2020-03-26 2024-04-10 LEK Pharmaceuticals d.d. Dimaleate form of 1-((2r,4r)-2-(1h-benzo[d]imidazol-2-yl)-1-methylpiperidin-4-yl)-3-(4-cyanophenyl)urea
WO2023002362A1 (en) 2021-07-22 2023-01-26 Pfizer Inc. Treatment of hematological malignancy
WO2023017541A1 (en) * 2021-08-12 2023-02-16 Msn Laboratories Private Limited, R&D Center Improved process for the preparation of 1-((2r,4r)-2-(1h-benzo[d]imidazol-2-yl)-1-methyl piperidin-4-yl)-3-(4-cyanophenyl)urea maleate
CN114668849B (zh) * 2021-12-31 2024-01-23 中国人民解放军军事科学院军事医学研究院 Shh通路调控生物节律及其相关应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0325956D0 (en) * 2003-11-06 2003-12-10 Addex Pharmaceuticals Sa Novel compounds
US8253800B2 (en) 2006-06-28 2012-08-28 Nikon Corporation Tracking device, automatic focusing device, and camera
ME00962B (me) * 2007-06-29 2012-06-20 Pfizer Benzimidazolski derivati
BR112017021075B1 (pt) * 2015-04-24 2021-08-03 Pfizer Inc. Forma cristalina de maleato de 1-((2r,4r)-2-(1h- benzo[d]imidazol-2-il)-1-metilpiperidin-4-il)-3-(4- cianofenil)ureia e composição farmacêutica

Also Published As

Publication number Publication date
RU2017137269A (ru) 2019-05-24
IL255224A0 (en) 2017-12-31
PT3666768T (pt) 2022-07-22
MX2017013645A (es) 2018-03-08
JP6345728B2 (ja) 2018-06-20
US11891372B2 (en) 2024-02-06
PT3286176T (pt) 2020-02-24
PL3286176T3 (pl) 2020-11-30
PL3666768T3 (pl) 2022-09-19
AU2016251940B2 (en) 2018-08-30
CY1125333T1 (el) 2025-03-28
TW201702238A (zh) 2017-01-16
IL255224B (en) 2021-01-31
RU2017137269A3 (enExample) 2019-09-13
CY1124056T1 (el) 2022-03-24
WO2016170451A1 (en) 2016-10-27
NZ735719A (en) 2020-11-27
BR112017021075A2 (pt) 2018-07-03
US20190382368A1 (en) 2019-12-19
US20220024893A1 (en) 2022-01-27
SG11201707863QA (en) 2017-11-29
ES2774053T3 (es) 2020-07-16
BR112017021075B1 (pt) 2021-08-03
KR20170129245A (ko) 2017-11-24
AU2016251940C1 (en) 2019-04-11
EP3666768A1 (en) 2020-06-17
EP3286176B1 (en) 2020-01-15
ES2923593T3 (es) 2022-09-28
ZA201706391B (en) 2020-12-23
HUE048664T2 (hu) 2020-07-28
EP3666768B1 (en) 2022-06-15
SI3666768T1 (sl) 2022-09-30
JP2016204373A (ja) 2016-12-08
DK3286176T3 (da) 2020-03-02
CN107531667A (zh) 2018-01-02
RU2717564C2 (ru) 2020-03-24
EP3286176A1 (en) 2018-02-28
KR20190038677A (ko) 2019-04-08
US10414748B2 (en) 2019-09-17
MX375384B (es) 2025-03-06
DK3666768T3 (da) 2022-06-27
HK1243416A1 (zh) 2018-07-13
US20180086731A1 (en) 2018-03-29
US20220024894A1 (en) 2022-01-27
AU2016251940A1 (en) 2017-10-12
TWI646093B (zh) 2019-01-01
CA2983387A1 (en) 2016-10-27
CA2927736A1 (en) 2016-10-24
US11168066B2 (en) 2021-11-09
KR102078444B1 (ko) 2020-02-17
AR104391A1 (es) 2017-07-19
SI3286176T1 (sl) 2020-04-30
US11891373B2 (en) 2024-02-06
CA2983387C (en) 2022-08-16

Similar Documents

Publication Publication Date Title
IL288104A (en) Heterocyclic compounds, preparation methods and their use
HUE059506T2 (hu) Az 1-((2R,4R)-2-(1H-benzo[d]imidazol-2-il)-1-metilpiperidin-4-il)-3-(4--cianofenil)karbamid-maleát kristályos formájának elõállítási eljárása és az 1-((2R,4R)-2-(1H-benzo[d]imidazol-2-il)-1-metilpiperidin-4-il)-3-(4--cianofenil)karbamid-imidazol komplex (1:1) kristályos formája
GB2572305B (en) Heterocyclic urea compound, and drug composition and application thereof
PT3580208T (pt) Derivados de 2-(3-(1h-benzo[d]imidazol-1-il)propil)piperidin-3-ol e compostos relacionados como inibidores de prs para tratamento de, por exemplo, cancro
IL271399A (en) Methods for the preparation of heterocyclic 3,1-benzodioxole compounds
PL3135110T3 (pl) Pochodne 1,7-diarylo-1,6-heptadieno-3,5-dionu, sposób ich wytwarzania i ich zastosowanie
HUE052833T2 (hu) Eljárás 2,5-furándikarbonsav (FDCA) elõállítására
HUE063043T2 (hu) Eljárás N-(5-(4-(4-formil-3-fenil-1H-pirazol-1-il)-pirimidin-2-il-amino)-4-metoxi-2-morfolinofenil)-akrilamid elõállítására
PH12016502347A1 (en) 1 -(cyclopent-2-en-1 -yl)-3-(2-hydroxy-3-(arylsulfonyl)phenyl)urea derivatives as cxcr2 inhibitors
SI3717476T1 (sl) Postopek priprave 2-(5-metoksiizokroman-1-il)-4,5-dihidro-1H-imidazola in njegove hidrogensulfatne soli
EP3354647A4 (en) EGFR KINASE INHIBITOR AND MANUFACTURING METHOD AND USE THEREOF
EP3373996A4 (en) METHOD AND SYSTEM FOR THE PRODUCTION, USE AND RELEASE OF ACTIVATED STEM CELLS
DK3259255T3 (da) (2r,4r)-5-(5'-chlor-2'-fluorbiphenyl-4-yl)-2-hydroxy-4-[(5-methyloxazol-2-carbonyl)amino]pentansyre
IL263356A (en) A crystalline form of a compound that suppresses protein kinase activity, and its application
IL251249B (en) Process for the preparation of 1-(3,5-dichloro-4-fluoro-phenyl)-2,2,2-trifluoro-ethanone
EP3504969A4 (en) COMPOSITION, METHOD, AND USE FOR COMBATING FUNGI INFECTIONS CAUSED BY BYNOSEMA CERANAE
IL251176B (en) A process for the preparation of 1-(3,5-dichlorophenyl)-2,2,2-trifluoroethanone and its history
HK1245073A1 (zh) 药物组合物
EP3336088A4 (en) CRYSTAL FORM OF OREXINE-RECEPTOR ANTAGONIST COMPOUND AND METHOD OF MANUFACTURE AND APPLICATION THEREOF
FR3038835B3 (fr) Composition de shampoing comprenant au moins un sel d'ammonium d'oligoester
DK3655395T3 (da) Fremgangsmåde til fremstilling af n-((1r,2s,sr)-5-(tert-butylamino)-2-((s)-3-(7- tert-butylpyrazolo[1,5-a][1,3,5]triazin-4-ylamino)-2-oxopyrrolidin-1- yl)cyclohexyl)acetamid
IT201700050223A1 (it) Procedimento per la preparazione di dexlansoprazolo cristallino
ZA201808625B (en) Crystalline form of compound suppressing protein kinase activity, and application thereof
EA201692217A1 (ru) Полиморфные формы фуразидина